Abstract:

1. The effects of 2-2-(1-(ethoxycarbonyl)-3-phenylpropyl)-[amino-oxopropyl]-6,7-dimethoxy- 1,2,3,4-tetrahydroisoquinoline-3 carboxylic acid (moexiprilat), 17beta-oestradiol (E2), oestrone (ES) and angiotensin II (AII) on growth and activation of oestrogen receptors and the immediate-early gene egr-1 were investigated in neonatal rat cardiac fibroblasts of female and male origin. 2. In BrdU proliferation assays, oestrone (10(-7)- 10(-9) M) stimulated cardiac fibroblast growth in a concentration-dependent fashion (maximum at 10(-7) M, 4.0 fold +/- 0.14 in female and 3.1 fold +/- 0.06 in male cells, n=9, P<0.05), while E2 (10(-7)-10(-9) M) had no effect. Moexiprilat (10(-7)M) completely inhibited oestrone-induced cardiac fibroblast growth. 3. Angiotensin II (10(-7) M) induced cardiac fibroblast growth (female 4.1 fold +/- 0.1/male 3.9 fold +/- 0.2; n=9, P<0.05). Angiotensin II induced oestrogen receptor (maximum 21.8 fold at 60 min) and egr-1 (maximum 47.5 fold at 60 min) expression in a time-dependent fashion. 4. In immunoblot experiments, oestrogen activated oestrogen receptor (ES: 12.8 fold +/- 2.0; E2: 14.7 fold +/- 4.9; n=3, P<0.05) and egr-1 (ES: 5.1 fold, +/- 0.24; E2: 3.8 fold, +/- 0.25; n=3, P<0.05) expression. The induction of oestrogen receptor and egr-1 protein expression was time-dependent and inhibited by moexiprilat. 5. Our results show that oestrone and 17beta-oestradiol reveal a significant difference in their potential to activate cardiac fibroblast growth in female and male cells and that oestrone-stimulated growth is inhibited by moexiprilat. The inhibition of oestrone-stimulated cardiac fibroblast growth by moexiprilat may contribute to the beneficial effects seen in postmenopausal women with hypertensive heart disease treated with ACE inhibitors.

Open in

PUBMED | DOI | PMC | Google Scholar | Wikipedia

Relations:

Content

Citations

(6)

Chemicals

(10)

Organisms

(3)

Processes

(1)

Anatomy

(2)

Affiliates

(1)

Effects of moexiprilat on oestrogen-stimulated cardiac fibroblast growth

Abstract

The effects of 2-2-(1-(ethoxycarbonyl)-3-phenylpropyl)-[amino-oxopropyl]−6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3 carboxylic acid (moexiprilat), 17β-oestradiol (E₂), oestrone (ES) and angiotensin II (AII) on growth and activation of oestrogen receptors and the immediate-early gene egr-1 were investigated in neonatal rat cardiac fibroblasts of female and male origin.
In BrdU proliferation assays, oestrone (10^–10M) stimulated cardiac fibroblast growth in a concentration-dependent fashion (maximum at 10M, 4.0 fold±0.14 in female and 3.1 fold±0.06 in male cells, n=9, P<0.05), while E₂ (10^–10M) had no effect. Moexiprilat (10M) completely inhibited oestrone-induced cardiac fibroblast growth.
Angiotensin II (10M) induced cardiac fibroblast growth (female 4.1 fold±0.1/male 3.9 fold±0.2; n=9, P<0.05). Angiotensin II induced oestrogen receptor (maximum 21.8 fold at 60 min) and egr-1 (maximum 47.5 fold at 60 min) expression in a time-dependent fashion.
In immunoblot experiments, oestrogen activated oestrogen receptor (ES: 12.8 fold±2.0; E₂: 14.7 fold±4.9; n=3, P<0.05) and egr-1 (ES: 5.1 fold,±0.24; E₂: 3.8 fold,±0.25; n=3, P<0.05) expression. The induction of oestrogen receptor and egr-1 protein expression was time-dependent and inhibited by moexiprilat.
Our results show that oestrone and 17β-oestradiol reveal a significant difference in their potential to activate cardiac fibroblast growth in female and male cells and that oestrone-stimulated growth is inhibited by moexiprilat. The inhibition of oestrone-stimulated cardiac fibroblast growth by moexiprilat may contribute to the beneficial effects seen in postmenopausal women with hypertensive heart disease treated with ACE inhibitors.

Keywords: Oestrogens, cardiac fibroblasts, moexiprilat, egr-1

Full Text

The Full Text of this article is available as a PDF (342K).

Medizinische Universitäts–Poliklinik, University of Bonn, Germany

^{Medizinische Klinik, University of Cologne, Germany}

^{Medizinische Klinik, University of Würzburg, Germany}

^{Author for correspondence:}

Received 1997 Feb 3; Revised 1997 Apr 17; Accepted 1997 Apr 21.

Abstract

The effects of 2-2-(1-(ethoxycarbonyl)-3-phenylpropyl)-[amino-oxopropyl]−6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3 carboxylic acid (moexiprilat), 17β-oestradiol (E₂), oestrone (ES) and angiotensin II (AII) on growth and activation of oestrogen receptors and the immediate-early gene egr-1 were investigated in neonatal rat cardiac fibroblasts of female and male origin.
In BrdU proliferation assays, oestrone (10^–10M) stimulated cardiac fibroblast growth in a concentration-dependent fashion (maximum at 10M, 4.0 fold±0.14 in female and 3.1 fold±0.06 in male cells, n=9, P<0.05), while E₂ (10^–10M) had no effect. Moexiprilat (10M) completely inhibited oestrone-induced cardiac fibroblast growth.
Angiotensin II (10M) induced cardiac fibroblast growth (female 4.1 fold±0.1/male 3.9 fold±0.2; n=9, P<0.05). Angiotensin II induced oestrogen receptor (maximum 21.8 fold at 60 min) and egr-1 (maximum 47.5 fold at 60 min) expression in a time-dependent fashion.
In immunoblot experiments, oestrogen activated oestrogen receptor (ES: 12.8 fold±2.0; E₂: 14.7 fold±4.9; n=3, P<0.05) and egr-1 (ES: 5.1 fold,±0.24; E₂: 3.8 fold,±0.25; n=3, P<0.05) expression. The induction of oestrogen receptor and egr-1 protein expression was time-dependent and inhibited by moexiprilat.
Our results show that oestrone and 17β-oestradiol reveal a significant difference in their potential to activate cardiac fibroblast growth in female and male cells and that oestrone-stimulated growth is inhibited by moexiprilat. The inhibition of oestrone-stimulated cardiac fibroblast growth by moexiprilat may contribute to the beneficial effects seen in postmenopausal women with hypertensive heart disease treated with ACE inhibitors.

Keywords: Oestrogens, cardiac fibroblasts, moexiprilat, egr-1

Abstract

Full Text

Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.

Learn More